PRISM BioLab Co.,LTD Income Statement

Financials in millions JPY. Fiscal year is October - September.

Millions JPY. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022
Revenue	677.33	305.62	112.93	554
Revenue Growth (YoY)	121.63%	170.64%	-79.62%	-
Cost of Revenue	407.57	145.08	32.62	19
Gross Profit	269.76	160.54	80.31	535
Selling, General & Admin	1,044	942.93	238.08	468
Research & Development	-	-	338.73	-
Operating Expenses	1,044	942.93	577.17	468
Operating Income	-774.45	-782.39	-496.87	67
Interest & Investment Income	5.3	0.36	0.02	-
Currency Exchange Gain (Loss)	21.5	-15.54	-0.77	13
Other Non Operating Income (Expenses)	-0.65	-34.1	0.07	-3
EBT Excluding Unusual Items	-748.3	-831.67	-497.55	77
Gain (Loss) on Sale of Assets	-	0.25	-0	-4
Asset Writedown	-82.98	-216.78	-28.15	-
Pretax Income	-831.28	-1,048	-525.7	73
Income Tax Expense	2.42	1.31	1.21	1
Net Income	-833.7	-1,050	-526.91	72
Net Income to Common	-833.7	-1,050	-526.91	72
Shares Outstanding (Basic)	37	31	28	27
Shares Outstanding (Diluted)	37	31	28	27
Shares Change (YoY)	16.70%	13.40%	0.94%	-
EPS (Basic)	-22.82	-33.53	-19.09	2.63
EPS (Diluted)	-22.82	-33.53	-19.09	2.63
Free Cash Flow	-1,533	-55.64	-548.4	-
Free Cash Flow Per Share	-41.97	-1.78	-19.87	-
Gross Margin	39.83%	52.53%	71.11%	96.57%
Operating Margin	-114.34%	-256.00%	-439.99%	12.09%
Profit Margin	-123.09%	-343.41%	-466.60%	13.00%
Free Cash Flow Margin	-226.34%	-18.21%	-485.63%	-
EBITDA	-	-773.65	-488.13	-
EBITDA Margin	-	-253.14%	-	-
D&A For EBITDA	-	8.74	8.74	-
EBIT	-774.45	-782.39	-496.87	67
EBIT Margin	-114.34%	-256.00%	-	12.09%
Effective Tax Rate	-	-	-	1.37%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.